Potent and selective inhibitor of DYRK1A (IC50 values are 80, 800 and 900 nM for DYRK1A, DYRK3 and DYRK2 respectively). Inhibits DYRK1A-mediated tau phosphorylation and regulates PPARγ expression. Also induces pancreatic beta cell proliferation. Exhibits antidiabetic activity. Orally bioavailable.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||1.06||5mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 212.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.71 mL||23.56 mL||47.11 mL|
|5 mM||0.94 mL||4.71 mL||9.42 mL|
|10 mM||0.47 mL||2.36 mL||4.71 mL|
|50 mM||0.09 mL||0.47 mL||0.94 mL|
References are publications that support the products' biological activity.
Smith et al (2012) Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem.Neurosci. 3 857 PMID: 23173067
Bain et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem.J. 408 297 PMID: 17850214
Waki et al (2007) The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression. Cell Metab. 5 357 PMID: 17488638
Wang et al (2015) A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat.Med. 21 383 PMID: 25751815
If you know of a relevant reference for Harmine, please let us know.
View Related Products by Product Action
Keywords: Harmine, supplier, Harmine, dyrk1a, dyrk, inhibitors, inhibits, potent, selective, dual, specificity, tyrosine, phosphorylation, regulated, kinase-1A, PPARg, PPARgamma, PPARγ, antidiabetic, Microtubules, DYRK, DYRK, Tocris Bioscience
Citations for Harmine
Citations are publications that use Tocris products.
Currently there are no citations for Harmine. Do you know of a great paper that uses Harmine from Tocris? If so please let us know.
Reviews for Harmine
There are currently no reviews for this product. Be the first to review Harmine and earn rewards!
Have you used Harmine?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.